News
RGEN
124.46
+1.41%
1.73
Weekly Report: what happened at RGEN last week (0518-0522)?
Weekly Report · 4d ago
Is Repligen’s (RGEN) New ESG Report Hinting at a Shift in Its Long-Term Capital Play?
Simply Wall St · 6d ago
Repligen CEO Loeillot presents at William Blair Growth Stock Conference
PUBT · 05/22 11:30
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Barchart · 05/22 06:30
3 Out-of-Favor Stocks We Keep Off Our Radar
Barchart · 05/22 04:38
Repligen publishes 2025 sustainability report
PUBT · 05/20 11:55
Repligen publishes 2025 corporate sustainability report with ESG disclosures
PUBT · 05/20 11:54
Repligen publishes 2025 corporate sustainability report
PUBT · 05/20 11:31
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Barchart · 05/20 06:30
Reassessing Repligen (RGEN) Valuation After A Steep Multi‑Month Share Price Pullback
Simply Wall St · 05/19 18:21
Weekly Report: what happened at RGEN last week (0511-0515)?
Weekly Report · 05/18 10:16
Repligen Price Target Announced at $160.00/Share by RBC Capital
Dow Jones · 05/15 14:24
RBC Capital Reinstates Outperform on Repligen, Announces $160 Price Target
Benzinga · 05/15 14:14
Repligen Shareholders Approve Directors, Auditor and Pay Plan
TipRanks · 05/15 12:28
Why Repligen (RGEN) Stock Is Trading Up Today
Barchart · 05/15 12:22
REPLIGEN CORP <RGEN.O>: RBC RESUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $160
Reuters · 05/15 04:00
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Cardiff Oncology (CRDF) and Meiragtx Holdings (MGTX)
TipRanks · 05/14 22:20
Q/C Technologies director Chelsea Sierra Voss acquires 1,753 shares for $5,521.95
PUBT · 05/14 21:34
Repligen resumed with an Outperform at RBC Capital
TipRanks · 05/14 20:55
Alger Mid Cap 40 ETF Q1 2026 Portfolio Movers
Seeking Alpha · 05/14 02:50
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.